General Information of Drug (ID: DM2FH10)

Drug Name
INBRX-105 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM2FH10

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Urelumab DM6RTVG B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Anti-CD137 DMHVZ27 Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
MG7-CART DME6PB0 Acute myeloid leukaemia 2A60 Phase 1/2 [5]
NM21-1480 DMDNJP5 Advanced solid tumour 2A00-2F9Z Phase 1/2 [6]
CD137 CAR-T Cell DMHMC19 Acute lymphoblastic leukaemia 2A85 Phase 1/2 [7]
ADG106 DM87H0S Non-hodgkin lymphoma 2B33.5 Phase 1/2 [8]
CD28 and CD137 CAR-T Cells DMFGQXB Acute lymphoblastic leukaemia 2A85 Phase 1 [9]
MCLA-145 DM8CGUV Lymphoma 2A80-2A86 Phase 1 [10]
GEN1046 DMEWRNZ Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
GEN1042 DMNP6T3 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Avelumab DMSZLJR Merkel cell carcinoma 2C34 Approved [12]
Durvalumab DM4PVDY Urothelial carcinoma 2C92.0 Approved [13]
RG-7446 DM69XMQ Urothelial carcinoma 2C92.0 Approved [14]
Bavencio DMU9C8F Merkel cell carcinoma 2C34 Approved [15]
Atezolizumab DMMF8U0 Non-small-cell lung cancer 2C25 Approved [16]
Sugemalimab DMH5YQ3 Non-small-cell lung cancer 2C25 Approved in China [17]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [18]
MEDI4736 DM5X849 Solid tumour/cancer 2A00-2F9Z Phase 3 [19]
MPDL-3280A DM9K3LM Melanoma 2C30 Phase 3 [20]
CS1001 DMSY0NE Non-small-cell lung cancer 2C25 Phase 3 [21]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Co-stimulatory molecule 4-1BB (CD137) TTPW9LJ TNR9_HUMAN Agonist [2]
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03809624) Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Inhibrx.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
5 ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
6 Clinical pipeline report, company report or official report of Numab Therapeutics.
7 ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
8 Clinical pipeline report, company report or official report of Adagene.
9 ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
10 Clinical pipeline report, company report or official report of Merus.
11 Clinical pipeline report, company report or official report of Genmab.
12 Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
15 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
17 Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
18 Clinical pipeline report, company report or official report of Alphamab Oncology.
19 National Cancer Institute Drug Dictionary (drug id 740856).
20 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
21 GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.